In a pre-proof of a forthcoming journal article, members of the European College of Neuropsychopharmacology (ECNP) including European Medicines Agency’s Chief Medical Officer, Steffen Thirstrup, discuss knowledge
Like many things, 2023 simultaneously passed in a flash yet also seems like an era ago. When I looked back through our coverage in preparation
This Issue is a relatively long one, as it’s something of a catch-up for the holiday period. We look at psychedelic drug development news from
Our Top 10 Psychedelics Articles in 2023January 11, 2024 To kick off our 2023 Year in Review, Josh looks back at some of our top
*** December’s meeting of the full Natural Medicine Advisory Board began with a handful of administrative updates from the Program Director, Attorney General’s office, and
“A response can be expected within 30 business days after the Panel meeting”, according to the Attorney General’s office. That’s up to six weeks without
We added 47 PCTs and 26 US patent applications focused on psychedelics to our tracker in the month of November 2023. New entries came from
Amy, Henry and Protik then took to the stage, with Emerson kicking off a fireside-type discussion with the Helena executives. But why had Helena, which
A Phase II trial affirmed the safety and efficacy of psilocybin-assisted therapy in a group setting, with a majority experiencing sustained response and remission from
According to atai, this investment “reinforces atai’s position as the biopharmaceutical company with the largest and most diverse portfolio of clinical-stage psychedelic candidates”. It might